Skip to main content

Table 1 Demographic and clinical characteristics

From: Dispensing patterns of drugs used for neuropathic pain and adherence to NeuPSIG guideline: an observational study

Demographics and clinical variables (N,%) unless otherwise specified

Age (mean, SD)

50.22 (14.17)

Female

198 (55)

Marital status

 Single

64 (17.8)

 Married

296 (82.2)

Current smoker

250 (69.4)

Alcohol consumption

 Abstainer

256 (71.1)

 Drinker

102 (28.3)

Lebanese governorate

 Beirut

126 (35)

 Bekaa

93 (25.8)

 Mount Lebanon

85 (23.6)

 North Lebanon

27 (7.5)

 Nabatiye

15 (4.2)

 South Lebanon

14 (3.9)

Comorbidities

 Diabetes mellitus

110 (30.6)

 Anxiety

108 (30)

 Depression

24 (9.4)

First-line agents

 Any

278 (77.2)

 Pregabalin

218 (60.5)

 Gabapentin

48 (13.3)

 Tricyclic antidepressants

6 (1.7)

 Duloxetine

4 (1.1)

 Venlafaxine

2 (0.6)

Second-line agents

 

 Tramadol

57 (15.8)

Other agents

 

 NSAIDs

169 (46.8)

 Topical agents (Capsaicin, Lidocaine)

20 (5.5)

The most common drug combination used to treat neuropathic pain disorders

 Dual: Gabapentinoids + NSAIDS

78 (21.6)

 Gabapentinoids + Tramadol

32 (8.9)

 Triple: Gabapentinoids + NSAIDS + Tramadol

22 (6.1)

 Quadruple: Gabapentinoids + NSAIDS + Tramadol + topical agents

18 (5)

Medication dispensing

 

 Prescription (orthopedist, neurologist, neurosurgeon)

300 (83.5)

 No prescription

60 (16.5)

Medication utilization duration

 < 1 month

40 (11.1)

 < 6 months

132 (36.7)

 6 months–1 year

94 (26.1)

 > 1 year

94 (26.1)

  1. NSAIDs nonsteroidal anti-inflammatory drugs, SD Standard deviation